This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Based on the druggability of DR3penA, we sought to investigate its effects on respirable particulate silicon dioxide (SiO 2 )- and soluble chemical paraquat (PQ)-induced pulmonary fibrosis in this study by using western blot, RT-qPCR, immunofluorescence, H&E and Masson staining, immunohistochemistry and serum biochemicalassays.
This includes treatments or therapeutics that are intended to serve a specific population that can only be selected (or excluded) via diagnostic guidelines, products for which a diagnostic could identify high-risk patients, and/or those that require monitoring for treatment adjustments. For now, LDTs are filling the gap.
Å resolution) 6 is now being targeted for small molecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemicalassays. NIH R01 DA048153 (to D.P.S.), Epub 20230720. doi: 10.1128/jcm.01269-22.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content